Ibogaine

Ibogaine is a psychedelic drug that is currently under review for its potential therapeutic applications, particularly in treating post-traumatic stress disorder (PTSD). It is newsworthy due to President Trump's recent executive order directing the FDA to expedite the review process for psychedelic drugs, including ibogaine. This action comes amid growing support from US military veteran groups and some conservative lawmakers who believe ibogaine can offer significant benefits for veterans struggling with PTSD. Despite this support, ibogaine remains a controversial substance, as it is currently classified under the federal government's most restrictive category for illegal, high-risk drugs and has known safety risks. The administration's move to expedite its review signifies a potential shift in the regulatory landscape surrounding psychedelic drugs and their potential medical uses, highlighting the ongoing debate between potential benefits and safety concerns.